Inetetamab may also be an option for neoadjuvant treatment of HER2-positive breast cancer patients, considering the combination of chemotherapeutic agents, the appropriate treatment duration, and the management of safety and adverse effects during the neoadjuvant phase. This evidence concerns the gene ERBB2 and breast carcinoma.